-
Interaction between host genetics and drug therapy in influencing gut bacterial diversity
-
The role of genetic variation in VKORC1 and GGCX on warfarin response in a South African population
-
Type 2 diabetes mellitus and dyslipidaemia: effects of genetic variation in African populations
-
Pharmacogenetics of resistant hypertension: evaluating the role of genetic variation in ABCB1, ADBR1, CES1, CYP3A4, CYP3A5, NEDD4L, NOS3, NR3C2 and SCNN1B among South African hypertensive patient
-
The pharmacologenetics of lopinavir in a cohort of black African HIV/AIDS patients
-
Human host and malaria parasite genome variations to susceptibility to malaria
-
Pharmacogenomics of warfarin: comprehensive evaluation of important warfarin genomic response factors
-
Chemotherapeutic drugs, 5-fluorouracil and cisplatin, differentially affect exprssion of drug metabolising enzyme genes in an oesophageal cancer cell line
-
Virus restriction gene variants and their possible role in neurocognitive function in children born to HIV-infected mothers
-
Determining the role of differential expression of candidate icroRNAs in cardiometabolic diseases among South African adults living with HIV
-
Role of antiretroviral therapy exposure host genetics on cytomegalovirus infection status and association with gut microbiome profiles among pregnant black African women
-
Associations of genetic variants in ABCB1, ABCG2, CYP3A4, CYP3A5, and SLCO1B1 with statin-associated muscle symptom (SAMS) in South African populations
-
Pharmacogenetics of stavundine : role of genetic variation in mitochondrial DNA and polymerase gamma among adult Malawian HIV/AIDS patients
-
Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients
-
APOE, PCSK9, and CETP genetic variants as potential biomarkers of dyslipidaemia in black South Africans with Type 2 Diabetes Mellitus
